Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Olencki

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Investigational New Drugs|June 9, 1999
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancerK Rajagopalan, D Peereboom, G T Budd, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 1994
Amifostine: potential for clinically useful cytoprotectionG T Budd, V Lorenzi, R Ganapathi, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2000
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancerR Pelley, R Ganapathi, L Wood, et al.
Cancer|March 15, 1996
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinomaE Wos, T Olencki, L Tuason, et al.
Clinical Pharmacology and Therapeutics|March 7, 2007
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha familyP Masci, T Olencki, L Wood, et al.
Cancer|September 26, 1997
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsG T Budd, R Ganapathi, D J Adelstein, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 13, 2015
MicroRNA expression profiling in metastatic cutaneous squamous cell carcinomaJ Gillespie, L E Skeeles, D C Allain, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Investigational New Drugs|June 9, 1999
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancerK Rajagopalan, D Peereboom, G T Budd, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 1994
Amifostine: potential for clinically useful cytoprotectionG T Budd, V Lorenzi, R Ganapathi, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2000
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancerR Pelley, R Ganapathi, L Wood, et al.
Cancer|March 15, 1996
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinomaE Wos, T Olencki, L Tuason, et al.
Clinical Pharmacology and Therapeutics|March 7, 2007
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha familyP Masci, T Olencki, L Wood, et al.
Cancer|September 26, 1997
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsG T Budd, R Ganapathi, D J Adelstein, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 13, 2015
MicroRNA expression profiling in metastatic cutaneous squamous cell carcinomaJ Gillespie, L E Skeeles, D C Allain, et al.
Pageof 3